Long before the current debate on health care started, there was a different war brewing. For decades, people have been fighting over which program and plan is best: healthcare provided to government workers, military personnel or civilians?
The UK Financial Times this week (March 18) flagged up data from Withers & Rogers, a London-based IP firm, showing how the numbers of patent filings from the ten leading pharma companies has dropped in recent years.
As the health insurance marketplaces begin enrollment this week and go live on January 1, 2014, several issues continue to be a source of significant confusion to manufacturers, payers and the millions of consumers purchasing health insurance for the first time through an exchange.
Any pricing or revenue management initiative is only as good as the information on which it is based.
William Looney’s posting for this blog, “Calculating the Cost of R&D: Defending Tufts Research” (January 11, 2012), raises a number of interesting and important points.
Over the last few years I’ve worked with pharma marketers trying to preach and teach the virtues of digital channels. It has been a thankless task, with bucket loads of blood, sweat, and tears of frustration.
Susan Crowley reviews the hotly debated agenda items from last month's World Health Assembly (WHA) in Geneva, Switzerland.
The 2017 GPS ranking evaluates clinical trial registration, results reporting, clinical study report synopsis sharing, and journal article publication rates for new drugs approved by the Food and Drug Administration in 2014 that were sponsored by large drug companies.
A prime opportunity for pharma to raise its strategic game in ESG.
Examining a new three-part formula to enable the supply chain function to manage market pressures while delivering on the bottom line.
Examining a new three-part formula to enable the supply chain function to manage market pressures while delivering on the bottom line.
In a follow-up to our November CEO profile, Novo Nordisk’s Jesper Høiland writes how pharma companies and insurers are learning to collaborate.
Brand success can hinge on discovering the deeper motivations of customers and addressing the cognitive biases that result.
Three key questions dominate the agency’s Breakthrough Therapy Designation program since its 2012 launch.
Keith Fern looks at how community clinics can be turned into research sites.
Rick Lynch, the Army General who led the Iraqi ‘surge’ campaign, cites nine lessons that pharma leaders can apply in today’s come-from-behind struggle for market share.
The European Commission’s (EC) decision to withdraw its investigation into the UK Government's Patent Box scheme is positive news for British innovators, writes Michael Jaeger.
Two commercial marketing experts discuss how this mission critical function must change to stay relevant in bringing new therapies to the patients who need them.
Lessons to launch by during a pandemic—or otherwise.
How will companies market similarity in a way that differentiates from the innovator? Customer experience may be the key.
Amid COVID-19, pressure for “socially responsible” pricing could temper investments in future urgent healthcare needs.
With hostile takeovers on the rise, Mike Straw argues that pharma boards have a huge role to play in managing the people issues.
Mark Gross offers a case study in using structured product labeling (SPL) to reduce time to market.
How pharma can finally put true meaning behind its juiced-up jargon and turn the bluster into reality, by Lundbeck's Timothy White.
A new PwC survey reveals a strong need to fully embrace alternative commercial methods-not in a blind frenzy but through careful evaluation of which new sales strategies have true innovative potential.
Explicitly tying strategic planning to resource allocation boosts bottom-line productivity for pharma.
A new PwC survey reveals a strong need to fully embrace alternative commercial methods-not in a blind frenzy but through careful evaluation of which new sales strategies have true innovative potential.
Why executives should make the US R&D tax credit part of their planning discussions, by Chai Hoang and Chris Bard.